Press releases
Announcements on our programs, partnerships and financings.
- Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion Therapy
- Dren Bio Receives Prestigious 2025 Prix Galien USA Award for Best Biotech Startup
- Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline (PDF, opens in a new tab)
- Dren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for Cancer
- Dren Bio Strengthens Leadership Team with Appointment of Amit Mehta, Ph.D., as Chief Operating Officer and Chief Business Officer
- Dren Bio Announces $65 Million Series B Financing to Advance its Lead Asset into the Clinic and to Accelerate Development of New Product Candidates from its Targeted Myeloid Engager and Phagocytosis Platform
- Dren Bio Announces Research Collaboration and License Agreement with Pfizer to Discover and Advance Multiple Therapeutic Antibodies Using its Targeted Myeloid Engager and Phagocytosis Platform for the Treatment of Cancer
- Series A investment round led by SR One and Taiho Ventures, LLC , with participation from existing investors 8VC and Mission BioCapital and new investors including BVF Partners L.P., HBM Healthcare Investments, and Alexandria Venture Investments